Discoveries and breakthroughs achieved by the CNIO’s research groups have resulted in new applications of proven benefit in the prevention and treatment of cancer and other diseases. Among recent advances, one can point to three new groups of kinase inhibitors with oncological applications. Another group of compounds may help in the treatment of obesity, steatosis and ageing. CNIO research results have already led to the creation of three spin-off companies; in particular an innovative approach to cancer therapy discovered by a group at the CNIO and licensed to one of these spin-offs has been green lighted to proceed to the clinical trial stage.
Protection of intellectual property rights plays an important part in increasing public awareness as well as guaranteeing the advance of CNIO technology and know-how to society and the adoption of innovative biomedical solutions. Currently, the CNIO holds patents in about thirty families, roughly 20% of which are being exploited at the present time. We also partner with the pharmaceutical industry in programmes that bring a substantial financial return to the Centre (23 million euros since 2012) at the same time that they enrich our innovation-driven institutional culture.
Innovation by the numbers
For further information concerning our technologies available for licensing, collaboration and co-development, please contact us at email@example.com